nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—obesity—type 2 diabetes mellitus	0.411	1	CtDrD
Phenylpropanolamine—ADRA2A—type 2 diabetes mellitus	0.106	0.59	CbGaD
Phenylpropanolamine—CYP1A2—type 2 diabetes mellitus	0.0733	0.41	CbGaD
Phenylpropanolamine—Amphetamine—Nateglinide—type 2 diabetes mellitus	0.0488	0.268	CrCrCtD
Phenylpropanolamine—Dextroamphetamine—Nateglinide—type 2 diabetes mellitus	0.0488	0.268	CrCrCtD
Phenylpropanolamine—Methamphetamine—Nateglinide—type 2 diabetes mellitus	0.0474	0.26	CrCrCtD
Phenylpropanolamine—L-Phenylalanine—Nateglinide—type 2 diabetes mellitus	0.0371	0.204	CrCrCtD
Phenylpropanolamine—DRD1—Bromocriptine—type 2 diabetes mellitus	0.032	0.236	CbGbCtD
Phenylpropanolamine—ADRB1—Bromocriptine—type 2 diabetes mellitus	0.0276	0.203	CbGbCtD
Phenylpropanolamine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0211	0.156	CbGbCtD
Phenylpropanolamine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0202	0.149	CbGbCtD
Phenylpropanolamine—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0114	0.0843	CbGbCtD
Phenylpropanolamine—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00901	0.0664	CbGbCtD
Phenylpropanolamine—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00852	0.0628	CbGbCtD
Phenylpropanolamine—CYP1A2—Losartan—type 2 diabetes mellitus	0.0058	0.0428	CbGbCtD
Phenylpropanolamine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00153	0.168	CbGeAlD
Phenylpropanolamine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00103	0.113	CbGeAlD
Phenylpropanolamine—DRD1—nerve—type 2 diabetes mellitus	0.000892	0.0979	CbGeAlD
Phenylpropanolamine—SLC6A3—nerve—type 2 diabetes mellitus	0.000716	0.0787	CbGeAlD
Phenylpropanolamine—SLC6A2—nerve—type 2 diabetes mellitus	0.000578	0.0635	CbGeAlD
Phenylpropanolamine—MAOA—nerve—type 2 diabetes mellitus	0.000533	0.0585	CbGeAlD
Phenylpropanolamine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000524	0.0575	CbGeAlD
Phenylpropanolamine—Amphetamine—CARTPT—type 2 diabetes mellitus	0.000478	0.274	CrCbGaD
Phenylpropanolamine—Phenelzine—AOC3—type 2 diabetes mellitus	0.000384	0.22	CrCbGaD
Phenylpropanolamine—MAOA—islet of Langerhans—type 2 diabetes mellitus	0.000258	0.0283	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Tolazamide—type 2 diabetes mellitus	0.000242	0.00577	CcSEcCtD
Phenylpropanolamine—Constipation—Acarbose—type 2 diabetes mellitus	0.000242	0.00576	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Ramipril—type 2 diabetes mellitus	0.000241	0.00574	CcSEcCtD
Phenylpropanolamine—ADRB1—cardiovascular system—type 2 diabetes mellitus	0.000238	0.0261	CbGeAlD
Phenylpropanolamine—Tension—Glipizide—type 2 diabetes mellitus	0.000235	0.00559	CcSEcCtD
Phenylpropanolamine—Nervousness—Glipizide—type 2 diabetes mellitus	0.000232	0.00553	CcSEcCtD
Phenylpropanolamine—Hallucination—Bromocriptine—type 2 diabetes mellitus	0.00023	0.00548	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Glimepiride—type 2 diabetes mellitus	0.000229	0.00545	CcSEcCtD
Phenylpropanolamine—Rash—Miglitol—type 2 diabetes mellitus	0.000227	0.0054	CcSEcCtD
Phenylpropanolamine—Dermatitis—Miglitol—type 2 diabetes mellitus	0.000227	0.00539	CcSEcCtD
Phenylpropanolamine—Vision blurred—Glipizide—type 2 diabetes mellitus	0.000225	0.00537	CcSEcCtD
Phenylpropanolamine—Tremor—Glipizide—type 2 diabetes mellitus	0.000224	0.00534	CcSEcCtD
Phenylpropanolamine—MAOA—retina—type 2 diabetes mellitus	0.000221	0.0242	CbGeAlD
Phenylpropanolamine—Tension—Glimepiride—type 2 diabetes mellitus	0.000219	0.00521	CcSEcCtD
Phenylpropanolamine—Tension—Sitagliptin—type 2 diabetes mellitus	0.000218	0.0052	CcSEcCtD
Phenylpropanolamine—Nervousness—Glimepiride—type 2 diabetes mellitus	0.000217	0.00516	CcSEcCtD
Phenylpropanolamine—Nervousness—Sitagliptin—type 2 diabetes mellitus	0.000216	0.00515	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.000214	0.00511	CcSEcCtD
Phenylpropanolamine—Nausea—Miglitol—type 2 diabetes mellitus	0.000214	0.00509	CcSEcCtD
Phenylpropanolamine—Drowsiness—Gliclazide—type 2 diabetes mellitus	0.000211	0.00504	CcSEcCtD
Phenylpropanolamine—Vision blurred—Glimepiride—type 2 diabetes mellitus	0.00021	0.00501	CcSEcCtD
Phenylpropanolamine—ADRB1—adipose tissue—type 2 diabetes mellitus	0.00021	0.0231	CbGeAlD
Phenylpropanolamine—Vision blurred—Sitagliptin—type 2 diabetes mellitus	0.00021	0.00499	CcSEcCtD
Phenylpropanolamine—Tremor—Glimepiride—type 2 diabetes mellitus	0.000209	0.00498	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.000208	0.00496	CcSEcCtD
Phenylpropanolamine—MAOA—nephron tubule—type 2 diabetes mellitus	0.000208	0.0228	CbGeAlD
Phenylpropanolamine—Arrhythmia—Bromocriptine—type 2 diabetes mellitus	0.000207	0.00492	CcSEcCtD
Phenylpropanolamine—Agitation—Glimepiride—type 2 diabetes mellitus	0.000205	0.00488	CcSEcCtD
Phenylpropanolamine—Rash—Tolbutamide—type 2 diabetes mellitus	0.000204	0.00486	CcSEcCtD
Phenylpropanolamine—Anxiety—Glipizide—type 2 diabetes mellitus	0.000203	0.00483	CcSEcCtD
Phenylpropanolamine—Constipation—Repaglinide—type 2 diabetes mellitus	0.000202	0.0048	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.000201	0.00478	CcSEcCtD
Phenylpropanolamine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000198	0.0217	CbGeAlD
Phenylpropanolamine—Tension—Bromocriptine—type 2 diabetes mellitus	0.000198	0.0047	CcSEcCtD
Phenylpropanolamine—Confusional state—Glipizide—type 2 diabetes mellitus	0.000197	0.00469	CcSEcCtD
Phenylpropanolamine—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.000196	0.00466	CcSEcCtD
Phenylpropanolamine—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.000195	0.00463	CcSEcCtD
Phenylpropanolamine—Dizziness—Tolazamide—type 2 diabetes mellitus	0.000195	0.00463	CcSEcCtD
Phenylpropanolamine—Nausea—Tolbutamide—type 2 diabetes mellitus	0.000192	0.00457	CcSEcCtD
Phenylpropanolamine—Ataxia—Losartan—type 2 diabetes mellitus	0.000192	0.00457	CcSEcCtD
Phenylpropanolamine—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.000191	0.00454	CcSEcCtD
Phenylpropanolamine—Vision blurred—Bromocriptine—type 2 diabetes mellitus	0.00019	0.00452	CcSEcCtD
Phenylpropanolamine—Anxiety—Glimepiride—type 2 diabetes mellitus	0.000189	0.00451	CcSEcCtD
Phenylpropanolamine—Anxiety—Sitagliptin—type 2 diabetes mellitus	0.000189	0.00449	CcSEcCtD
Phenylpropanolamine—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000188	0.0207	CbGeAlD
Phenylpropanolamine—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.000187	0.00445	CcSEcCtD
Phenylpropanolamine—MAOA—cardiovascular system—type 2 diabetes mellitus	0.000187	0.0205	CbGeAlD
Phenylpropanolamine—Rash—Tolazamide—type 2 diabetes mellitus	0.000185	0.00442	CcSEcCtD
Phenylpropanolamine—Rash—Chlorpropamide—type 2 diabetes mellitus	0.000185	0.00442	CcSEcCtD
Phenylpropanolamine—Agitation—Bromocriptine—type 2 diabetes mellitus	0.000185	0.00441	CcSEcCtD
Phenylpropanolamine—Confusional state—Glimepiride—type 2 diabetes mellitus	0.000184	0.00437	CcSEcCtD
Phenylpropanolamine—Rash—Linagliptin—type 2 diabetes mellitus	0.000184	0.00437	CcSEcCtD
Phenylpropanolamine—Dermatitis—Linagliptin—type 2 diabetes mellitus	0.000183	0.00437	CcSEcCtD
Phenylpropanolamine—MAOA—kidney—type 2 diabetes mellitus	0.000183	0.02	CbGeAlD
Phenylpropanolamine—MAOA—pancreas—type 2 diabetes mellitus	0.000181	0.0199	CbGeAlD
Phenylpropanolamine—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00018	0.00429	CcSEcCtD
Phenylpropanolamine—Vomiting—Acarbose—type 2 diabetes mellitus	0.00018	0.00428	CcSEcCtD
Phenylpropanolamine—Rash—Acarbose—type 2 diabetes mellitus	0.000178	0.00424	CcSEcCtD
Phenylpropanolamine—Dermatitis—Acarbose—type 2 diabetes mellitus	0.000178	0.00424	CcSEcCtD
Phenylpropanolamine—MAOA—cortex of kidney—type 2 diabetes mellitus	0.000178	0.0195	CbGeAlD
Phenylpropanolamine—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000178	0.00423	CcSEcCtD
Phenylpropanolamine—Drowsiness—Metformin—type 2 diabetes mellitus	0.000177	0.00421	CcSEcCtD
Phenylpropanolamine—Insomnia—Glipizide—type 2 diabetes mellitus	0.000176	0.0042	CcSEcCtD
Phenylpropanolamine—Flushing—Gliclazide—type 2 diabetes mellitus	0.000176	0.0042	CcSEcCtD
Phenylpropanolamine—Nausea—Tolazamide—type 2 diabetes mellitus	0.000175	0.00416	CcSEcCtD
Phenylpropanolamine—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000175	0.00416	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Glipizide—type 2 diabetes mellitus	0.000174	0.00414	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.000174	0.00414	CcSEcCtD
Phenylpropanolamine—Somnolence—Glipizide—type 2 diabetes mellitus	0.000173	0.00413	CcSEcCtD
Phenylpropanolamine—Vision blurred—Glyburide—type 2 diabetes mellitus	0.000173	0.00413	CcSEcCtD
Phenylpropanolamine—Vomiting—Nateglinide—type 2 diabetes mellitus	0.000173	0.00413	CcSEcCtD
Phenylpropanolamine—Tremor—Glyburide—type 2 diabetes mellitus	0.000172	0.00411	CcSEcCtD
Phenylpropanolamine—Rash—Nateglinide—type 2 diabetes mellitus	0.000172	0.00409	CcSEcCtD
Phenylpropanolamine—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.000172	0.00409	CcSEcCtD
Phenylpropanolamine—Anxiety—Bromocriptine—type 2 diabetes mellitus	0.000171	0.00407	CcSEcCtD
Phenylpropanolamine—Hypotension—Glimepiride—type 2 diabetes mellitus	0.00017	0.00405	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Gliclazide—type 2 diabetes mellitus	0.00017	0.00404	CcSEcCtD
Phenylpropanolamine—Insomnia—Pioglitazone—type 2 diabetes mellitus	0.000169	0.00403	CcSEcCtD
Phenylpropanolamine—Nausea—Acarbose—type 2 diabetes mellitus	0.000168	0.004	CcSEcCtD
Phenylpropanolamine—Constipation—Glipizide—type 2 diabetes mellitus	0.000167	0.00397	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Pioglitazone—type 2 diabetes mellitus	0.000167	0.00397	CcSEcCtD
Phenylpropanolamine—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000166	0.0182	CbGeAlD
Phenylpropanolamine—Confusional state—Bromocriptine—type 2 diabetes mellitus	0.000166	0.00395	CcSEcCtD
Phenylpropanolamine—Insomnia—Glimepiride—type 2 diabetes mellitus	0.000165	0.00392	CcSEcCtD
Phenylpropanolamine—MAOA—adipose tissue—type 2 diabetes mellitus	0.000165	0.0181	CbGeAlD
Phenylpropanolamine—Insomnia—Sitagliptin—type 2 diabetes mellitus	0.000164	0.00391	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Glimepiride—type 2 diabetes mellitus	0.000162	0.00387	CcSEcCtD
Phenylpropanolamine—Tension—Gliclazide—type 2 diabetes mellitus	0.000162	0.00386	CcSEcCtD
Phenylpropanolamine—Somnolence—Glimepiride—type 2 diabetes mellitus	0.000162	0.00386	CcSEcCtD
Phenylpropanolamine—Nausea—Nateglinide—type 2 diabetes mellitus	0.000162	0.00385	CcSEcCtD
Phenylpropanolamine—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.000161	0.00384	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Glipizide—type 2 diabetes mellitus	0.000161	0.00383	CcSEcCtD
Phenylpropanolamine—Nervousness—Gliclazide—type 2 diabetes mellitus	0.00016	0.00382	CcSEcCtD
Phenylpropanolamine—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.00016	0.00382	CcSEcCtD
Phenylpropanolamine—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000155	0.0037	CcSEcCtD
Phenylpropanolamine—Tremor—Gliclazide—type 2 diabetes mellitus	0.000155	0.00369	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.000154	0.00367	CcSEcCtD
Phenylpropanolamine—Hypotension—Bromocriptine—type 2 diabetes mellitus	0.000154	0.00366	CcSEcCtD
Phenylpropanolamine—Agitation—Gliclazide—type 2 diabetes mellitus	0.000152	0.00362	CcSEcCtD
Phenylpropanolamine—Confusional state—Glyburide—type 2 diabetes mellitus	0.000151	0.00361	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.00015	0.00357	CcSEcCtD
Phenylpropanolamine—Vomiting—Repaglinide—type 2 diabetes mellitus	0.00015	0.00357	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.00015	0.00356	CcSEcCtD
Phenylpropanolamine—Rash—Repaglinide—type 2 diabetes mellitus	0.000149	0.00354	CcSEcCtD
Phenylpropanolamine—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.000149	0.00354	CcSEcCtD
Phenylpropanolamine—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000149	0.00354	CcSEcCtD
Phenylpropanolamine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000147	0.00351	CcSEcCtD
Phenylpropanolamine—Flushing—Metformin—type 2 diabetes mellitus	0.000147	0.00351	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000146	0.00349	CcSEcCtD
Phenylpropanolamine—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000146	0.00348	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000144	0.00342	CcSEcCtD
Phenylpropanolamine—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000143	0.00341	CcSEcCtD
Phenylpropanolamine—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000141	0.00337	CcSEcCtD
Phenylpropanolamine—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000141	0.00335	CcSEcCtD
Phenylpropanolamine—Constipation—Bromocriptine—type 2 diabetes mellitus	0.00014	0.00335	CcSEcCtD
Phenylpropanolamine—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00014	0.00334	CcSEcCtD
Phenylpropanolamine—Hypotension—Glyburide—type 2 diabetes mellitus	0.00014	0.00334	CcSEcCtD
Phenylpropanolamine—Anxiety—Gliclazide—type 2 diabetes mellitus	0.00014	0.00334	CcSEcCtD
Phenylpropanolamine—Nausea—Repaglinide—type 2 diabetes mellitus	0.00014	0.00334	CcSEcCtD
Phenylpropanolamine—ADRA2A—pancreas—type 2 diabetes mellitus	0.000139	0.0153	CbGeAlD
Phenylpropanolamine—Flushing—Irbesartan—type 2 diabetes mellitus	0.000139	0.00331	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000138	0.00328	CcSEcCtD
Phenylpropanolamine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000136	0.015	CbGeAlD
Phenylpropanolamine—Confusional state—Gliclazide—type 2 diabetes mellitus	0.000136	0.00324	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000135	0.00322	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000134	0.0032	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000134	0.00319	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000134	0.00319	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000134	0.00319	CcSEcCtD
Phenylpropanolamine—Levonordefrin—ADRA2A—type 2 diabetes mellitus	0.000132	0.0759	CrCbGaD
Phenylpropanolamine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000132	0.00315	CcSEcCtD
Phenylpropanolamine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000132	0.00313	CcSEcCtD
Phenylpropanolamine—Flushing—Losartan—type 2 diabetes mellitus	0.000131	0.00312	CcSEcCtD
Phenylpropanolamine—Vision blurred—Metformin—type 2 diabetes mellitus	0.00013	0.0031	CcSEcCtD
Phenylpropanolamine—Tremor—Metformin—type 2 diabetes mellitus	0.00013	0.00308	CcSEcCtD
Phenylpropanolamine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000129	0.00307	CcSEcCtD
Phenylpropanolamine—Anxiety—Valsartan—type 2 diabetes mellitus	0.000129	0.00307	CcSEcCtD
Phenylpropanolamine—Tension—Irbesartan—type 2 diabetes mellitus	0.000128	0.00305	CcSEcCtD
Phenylpropanolamine—Anxiety—Orlistat—type 2 diabetes mellitus	0.000127	0.00303	CcSEcCtD
Phenylpropanolamine—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000127	0.00302	CcSEcCtD
Phenylpropanolamine—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000126	0.0139	CbGeAlD
Phenylpropanolamine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000126	0.003	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000126	0.003	CcSEcCtD
Phenylpropanolamine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000124	0.00295	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000124	0.00295	CcSEcCtD
Phenylpropanolamine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000124	0.00294	CcSEcCtD
Phenylpropanolamine—Rash—Glipizide—type 2 diabetes mellitus	0.000123	0.00293	CcSEcCtD
Phenylpropanolamine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000123	0.00293	CcSEcCtD
Phenylpropanolamine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000123	0.00293	CcSEcCtD
Phenylpropanolamine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000122	0.00291	CcSEcCtD
Phenylpropanolamine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000122	0.0029	CcSEcCtD
Phenylpropanolamine—Tension—Losartan—type 2 diabetes mellitus	0.00012	0.00287	CcSEcCtD
Phenylpropanolamine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00012	0.00287	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.00012	0.00286	CcSEcCtD
Phenylpropanolamine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00012	0.00286	CcSEcCtD
Phenylpropanolamine—Agitation—Irbesartan—type 2 diabetes mellitus	0.00012	0.00286	CcSEcCtD
Phenylpropanolamine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.00012	0.00286	CcSEcCtD
Phenylpropanolamine—Nervousness—Losartan—type 2 diabetes mellitus	0.000119	0.00284	CcSEcCtD
Phenylpropanolamine—ADRA1A—liver—type 2 diabetes mellitus	0.000116	0.0128	CbGeAlD
Phenylpropanolamine—Nausea—Glipizide—type 2 diabetes mellitus	0.000116	0.00276	CcSEcCtD
Phenylpropanolamine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000116	0.00276	CcSEcCtD
Phenylpropanolamine—Hypotension—Valsartan—type 2 diabetes mellitus	0.000116	0.00276	CcSEcCtD
Phenylpropanolamine—Vision blurred—Losartan—type 2 diabetes mellitus	0.000116	0.00276	CcSEcCtD
Phenylpropanolamine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000115	0.00275	CcSEcCtD
Phenylpropanolamine—MAOA—liver—type 2 diabetes mellitus	0.000115	0.0127	CbGeAlD
Phenylpropanolamine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000115	0.00275	CcSEcCtD
Phenylpropanolamine—Tremor—Losartan—type 2 diabetes mellitus	0.000115	0.00274	CcSEcCtD
Phenylpropanolamine—Rash—Glimepiride—type 2 diabetes mellitus	0.000115	0.00273	CcSEcCtD
Phenylpropanolamine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000115	0.00273	CcSEcCtD
Phenylpropanolamine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000114	0.00273	CcSEcCtD
Phenylpropanolamine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000114	0.00272	CcSEcCtD
Phenylpropanolamine—Agitation—Losartan—type 2 diabetes mellitus	0.000113	0.00269	CcSEcCtD
Phenylpropanolamine—Flushing—Ramipril—type 2 diabetes mellitus	0.000112	0.00267	CcSEcCtD
Phenylpropanolamine—Insomnia—Valsartan—type 2 diabetes mellitus	0.000112	0.00267	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000111	0.00265	CcSEcCtD
Phenylpropanolamine—Insomnia—Orlistat—type 2 diabetes mellitus	0.000111	0.00264	CcSEcCtD
Phenylpropanolamine—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000111	0.00264	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000111	0.00264	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.00011	0.00263	CcSEcCtD
Phenylpropanolamine—Somnolence—Valsartan—type 2 diabetes mellitus	0.00011	0.00262	CcSEcCtD
Phenylpropanolamine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000109	0.00259	CcSEcCtD
Phenylpropanolamine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000108	0.00258	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000108	0.00257	CcSEcCtD
Phenylpropanolamine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000108	0.00257	CcSEcCtD
Phenylpropanolamine—Constipation—Valsartan—type 2 diabetes mellitus	0.000106	0.00252	CcSEcCtD
Phenylpropanolamine—Hypotension—Metformin—type 2 diabetes mellitus	0.000105	0.00251	CcSEcCtD
Phenylpropanolamine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000104	0.00249	CcSEcCtD
Phenylpropanolamine—Anxiety—Losartan—type 2 diabetes mellitus	0.000104	0.00248	CcSEcCtD
Phenylpropanolamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000104	0.00247	CcSEcCtD
Phenylpropanolamine—Rash—Bromocriptine—type 2 diabetes mellitus	0.000104	0.00247	CcSEcCtD
Phenylpropanolamine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000103	0.00246	CcSEcCtD
Phenylpropanolamine—Tension—Ramipril—type 2 diabetes mellitus	0.000103	0.00246	CcSEcCtD
Phenylpropanolamine—Nervousness—Ramipril—type 2 diabetes mellitus	0.000102	0.00244	CcSEcCtD
Phenylpropanolamine—Confusional state—Losartan—type 2 diabetes mellitus	0.000101	0.00241	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000101	0.0024	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000101	0.0024	CcSEcCtD
Phenylpropanolamine—Somnolence—Metformin—type 2 diabetes mellitus	0.0001	0.00239	CcSEcCtD
Phenylpropanolamine—Hypotension—Irbesartan—type 2 diabetes mellitus	9.95e-05	0.00237	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	9.94e-05	0.00237	CcSEcCtD
Phenylpropanolamine—Tremor—Ramipril—type 2 diabetes mellitus	9.86e-05	0.00235	CcSEcCtD
Phenylpropanolamine—Tachycardia—Losartan—type 2 diabetes mellitus	9.78e-05	0.00233	CcSEcCtD
Phenylpropanolamine—Nausea—Bromocriptine—type 2 diabetes mellitus	9.76e-05	0.00232	CcSEcCtD
Phenylpropanolamine—Agitation—Ramipril—type 2 diabetes mellitus	9.67e-05	0.0023	CcSEcCtD
Phenylpropanolamine—Constipation—Metformin—type 2 diabetes mellitus	9.65e-05	0.0023	CcSEcCtD
Phenylpropanolamine—CYP1A2—liver—type 2 diabetes mellitus	9.63e-05	0.0106	CbGeAlD
Phenylpropanolamine—Vomiting—Glyburide—type 2 diabetes mellitus	9.55e-05	0.00227	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	9.49e-05	0.00226	CcSEcCtD
Phenylpropanolamine—Rash—Glyburide—type 2 diabetes mellitus	9.47e-05	0.00226	CcSEcCtD
Phenylpropanolamine—Somnolence—Irbesartan—type 2 diabetes mellitus	9.47e-05	0.00225	CcSEcCtD
Phenylpropanolamine—Dermatitis—Glyburide—type 2 diabetes mellitus	9.46e-05	0.00225	CcSEcCtD
Phenylpropanolamine—Hypotension—Losartan—type 2 diabetes mellitus	9.36e-05	0.00223	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Metformin—type 2 diabetes mellitus	9.3e-05	0.00221	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	9.13e-05	0.00217	CcSEcCtD
Phenylpropanolamine—Constipation—Irbesartan—type 2 diabetes mellitus	9.11e-05	0.00217	CcSEcCtD
Phenylpropanolamine—Insomnia—Losartan—type 2 diabetes mellitus	9.06e-05	0.00216	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	9.02e-05	0.00215	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Losartan—type 2 diabetes mellitus	8.93e-05	0.00213	CcSEcCtD
Phenylpropanolamine—Anxiety—Ramipril—type 2 diabetes mellitus	8.93e-05	0.00213	CcSEcCtD
Phenylpropanolamine—Nausea—Glyburide—type 2 diabetes mellitus	8.92e-05	0.00212	CcSEcCtD
Phenylpropanolamine—Dizziness—Gliclazide—type 2 diabetes mellitus	8.92e-05	0.00212	CcSEcCtD
Phenylpropanolamine—Somnolence—Losartan—type 2 diabetes mellitus	8.91e-05	0.00212	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	8.77e-05	0.00209	CcSEcCtD
Phenylpropanolamine—Confusional state—Ramipril—type 2 diabetes mellitus	8.66e-05	0.00206	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—ADRA2A—type 2 diabetes mellitus	8.59e-05	0.0492	CrCbGaD
Phenylpropanolamine—Vomiting—Gliclazide—type 2 diabetes mellitus	8.57e-05	0.00204	CcSEcCtD
Phenylpropanolamine—Constipation—Losartan—type 2 diabetes mellitus	8.57e-05	0.00204	CcSEcCtD
Phenylpropanolamine—Rash—Gliclazide—type 2 diabetes mellitus	8.5e-05	0.00203	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gliclazide—type 2 diabetes mellitus	8.5e-05	0.00202	CcSEcCtD
Phenylpropanolamine—Tachycardia—Ramipril—type 2 diabetes mellitus	8.39e-05	0.002	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Losartan—type 2 diabetes mellitus	8.26e-05	0.00197	CcSEcCtD
Phenylpropanolamine—Dizziness—Valsartan—type 2 diabetes mellitus	8.19e-05	0.00195	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—TNF—type 2 diabetes mellitus	8.14e-05	0.0466	CrCbGaD
Phenylpropanolamine—Dizziness—Orlistat—type 2 diabetes mellitus	8.1e-05	0.00193	CcSEcCtD
Phenylpropanolamine—Hypotension—Ramipril—type 2 diabetes mellitus	8.03e-05	0.00191	CcSEcCtD
Phenylpropanolamine—Nausea—Gliclazide—type 2 diabetes mellitus	8.01e-05	0.00191	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2E1—type 2 diabetes mellitus	7.89e-05	0.0452	CrCbGaD
Phenylpropanolamine—Vomiting—Valsartan—type 2 diabetes mellitus	7.88e-05	0.00188	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	7.84e-05	0.00187	CcSEcCtD
Phenylpropanolamine—Rash—Valsartan—type 2 diabetes mellitus	7.81e-05	0.00186	CcSEcCtD
Phenylpropanolamine—Dermatitis—Valsartan—type 2 diabetes mellitus	7.8e-05	0.00186	CcSEcCtD
Phenylpropanolamine—Vomiting—Orlistat—type 2 diabetes mellitus	7.78e-05	0.00185	CcSEcCtD
Phenylpropanolamine—Insomnia—Ramipril—type 2 diabetes mellitus	7.77e-05	0.00185	CcSEcCtD
Phenylpropanolamine—Rash—Orlistat—type 2 diabetes mellitus	7.72e-05	0.00184	CcSEcCtD
Phenylpropanolamine—Dermatitis—Orlistat—type 2 diabetes mellitus	7.71e-05	0.00184	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Ramipril—type 2 diabetes mellitus	7.66e-05	0.00182	CcSEcCtD
Phenylpropanolamine—Somnolence—Ramipril—type 2 diabetes mellitus	7.64e-05	0.00182	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP1A2—type 2 diabetes mellitus	7.51e-05	0.043	CrCbGaD
Phenylpropanolamine—Dizziness—Metformin—type 2 diabetes mellitus	7.46e-05	0.00178	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Losartan—type 2 diabetes mellitus	7.38e-05	0.00176	CcSEcCtD
Phenylpropanolamine—Nausea—Valsartan—type 2 diabetes mellitus	7.36e-05	0.00175	CcSEcCtD
Phenylpropanolamine—Constipation—Ramipril—type 2 diabetes mellitus	7.35e-05	0.00175	CcSEcCtD
Phenylpropanolamine—Nausea—Orlistat—type 2 diabetes mellitus	7.27e-05	0.00173	CcSEcCtD
Phenylpropanolamine—Vomiting—Metformin—type 2 diabetes mellitus	7.17e-05	0.00171	CcSEcCtD
Phenylpropanolamine—Rash—Metformin—type 2 diabetes mellitus	7.11e-05	0.00169	CcSEcCtD
Phenylpropanolamine—Dermatitis—Metformin—type 2 diabetes mellitus	7.11e-05	0.00169	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	7.08e-05	0.00169	CcSEcCtD
Phenylpropanolamine—Dizziness—Irbesartan—type 2 diabetes mellitus	7.04e-05	0.00168	CcSEcCtD
Phenylpropanolamine—Vomiting—Irbesartan—type 2 diabetes mellitus	6.77e-05	0.00161	CcSEcCtD
Phenylpropanolamine—Rash—Irbesartan—type 2 diabetes mellitus	6.71e-05	0.0016	CcSEcCtD
Phenylpropanolamine—Dermatitis—Irbesartan—type 2 diabetes mellitus	6.71e-05	0.0016	CcSEcCtD
Phenylpropanolamine—Nausea—Metformin—type 2 diabetes mellitus	6.7e-05	0.0016	CcSEcCtD
Phenylpropanolamine—Dizziness—Losartan—type 2 diabetes mellitus	6.63e-05	0.00158	CcSEcCtD
Phenylpropanolamine—Methamphetamine—ADRA2A—type 2 diabetes mellitus	6.45e-05	0.037	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP2E1—type 2 diabetes mellitus	6.38e-05	0.0365	CrCbGaD
Phenylpropanolamine—Vomiting—Losartan—type 2 diabetes mellitus	6.37e-05	0.00152	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	6.33e-05	0.00151	CcSEcCtD
Phenylpropanolamine—Nausea—Irbesartan—type 2 diabetes mellitus	6.32e-05	0.00151	CcSEcCtD
Phenylpropanolamine—Rash—Losartan—type 2 diabetes mellitus	6.32e-05	0.0015	CcSEcCtD
Phenylpropanolamine—Dermatitis—Losartan—type 2 diabetes mellitus	6.31e-05	0.0015	CcSEcCtD
Phenylpropanolamine—Phentermine—CYP1A2—type 2 diabetes mellitus	6.29e-05	0.0361	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP1A2—type 2 diabetes mellitus	6.07e-05	0.0348	CrCbGaD
Phenylpropanolamine—Nausea—Losartan—type 2 diabetes mellitus	5.95e-05	0.00142	CcSEcCtD
Phenylpropanolamine—Dizziness—Ramipril—type 2 diabetes mellitus	5.68e-05	0.00135	CcSEcCtD
Phenylpropanolamine—Vomiting—Ramipril—type 2 diabetes mellitus	5.46e-05	0.0013	CcSEcCtD
Phenylpropanolamine—Rash—Ramipril—type 2 diabetes mellitus	5.42e-05	0.00129	CcSEcCtD
Phenylpropanolamine—Dermatitis—Ramipril—type 2 diabetes mellitus	5.41e-05	0.00129	CcSEcCtD
Phenylpropanolamine—Phenelzine—CYP2E1—type 2 diabetes mellitus	5.39e-05	0.0309	CrCbGaD
Phenylpropanolamine—Nausea—Ramipril—type 2 diabetes mellitus	5.1e-05	0.00122	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP3A4—type 2 diabetes mellitus	4.97e-05	0.0285	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP3A4—type 2 diabetes mellitus	4.02e-05	0.023	CrCbGaD
Phenylpropanolamine—Phenelzine—CYP3A4—type 2 diabetes mellitus	3.4e-05	0.0195	CrCbGaD
Phenylpropanolamine—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	2.54e-06	6.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.53e-06	6.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.53e-06	6.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.51e-06	6.3e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ALB—type 2 diabetes mellitus	2.49e-06	6.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.49e-06	6.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—C3—type 2 diabetes mellitus	2.49e-06	6.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	2.48e-06	6.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.48e-06	6.24e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.48e-06	6.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	2.48e-06	6.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.47e-06	6.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	2.47e-06	6.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.46e-06	6.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.45e-06	6.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.43e-06	6.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.42e-06	6.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.42e-06	6.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AGT—type 2 diabetes mellitus	2.41e-06	6.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	2.41e-06	6.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	2.4e-06	6.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	2.39e-06	6.01e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—NOS3—type 2 diabetes mellitus	2.38e-06	5.99e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3R1—type 2 diabetes mellitus	2.38e-06	5.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.38e-06	5.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	2.38e-06	5.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.37e-06	5.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.37e-06	5.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—LEP—type 2 diabetes mellitus	2.37e-06	5.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—type 2 diabetes mellitus	2.37e-06	5.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.36e-06	5.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AGT—type 2 diabetes mellitus	2.36e-06	5.94e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	2.35e-06	5.92e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	2.35e-06	5.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.35e-06	5.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.35e-06	5.91e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.35e-06	5.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.34e-06	5.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.33e-06	5.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.32e-06	5.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—type 2 diabetes mellitus	2.31e-06	5.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—LEP—type 2 diabetes mellitus	2.31e-06	5.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	2.31e-06	5.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	2.3e-06	5.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.3e-06	5.78e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	2.3e-06	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	2.29e-06	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	2.29e-06	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	2.29e-06	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.29e-06	5.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.29e-06	5.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	2.28e-06	5.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	2.28e-06	5.74e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	2.28e-06	5.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.28e-06	5.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.26e-06	5.67e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—INS—type 2 diabetes mellitus	2.25e-06	5.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	2.24e-06	5.63e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	2.24e-06	5.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.24e-06	5.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.23e-06	5.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	2.22e-06	5.58e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	2.21e-06	5.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.21e-06	5.56e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.21e-06	5.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.19e-06	5.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.18e-06	5.49e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—type 2 diabetes mellitus	2.18e-06	5.48e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.17e-06	5.47e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.17e-06	5.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	2.17e-06	5.46e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.16e-06	5.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.14e-06	5.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	2.13e-06	5.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	2.13e-06	5.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	2.12e-06	5.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.11e-06	5.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.1e-06	5.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	2.1e-06	5.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.08e-06	5.22e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.06e-06	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	2.06e-06	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.06e-06	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	2.06e-06	5.17e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	2.06e-06	5.17e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	2.06e-06	5.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	2.06e-06	5.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—INS—type 2 diabetes mellitus	2.02e-06	5.08e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	2.02e-06	5.08e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	2e-06	5.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.99e-06	5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.99e-06	5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—INS—type 2 diabetes mellitus	1.98e-06	4.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.97e-06	4.96e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.97e-06	4.95e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.97e-06	4.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.96e-06	4.93e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	1.96e-06	4.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.96e-06	4.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.95e-06	4.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.95e-06	4.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.95e-06	4.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.95e-06	4.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.94e-06	4.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.94e-06	4.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.92e-06	4.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.91e-06	4.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.91e-06	4.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.91e-06	4.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.91e-06	4.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	1.91e-06	4.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.9e-06	4.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.89e-06	4.76e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	1.88e-06	4.73e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.86e-06	4.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.86e-06	4.67e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.86e-06	4.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	1.85e-06	4.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.82e-06	4.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.82e-06	4.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	1.82e-06	4.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.82e-06	4.56e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	1.82e-06	4.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.81e-06	4.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	1.81e-06	4.54e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.81e-06	4.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.8e-06	4.54e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	1.78e-06	4.49e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	1.78e-06	4.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.78e-06	4.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.78e-06	4.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.78e-06	4.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.77e-06	4.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.77e-06	4.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.76e-06	4.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.73e-06	4.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.73e-06	4.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.71e-06	4.29e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.69e-06	4.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.68e-06	4.22e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.67e-06	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.67e-06	4.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	1.67e-06	4.19e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.66e-06	4.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	1.63e-06	4.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.63e-06	4.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.61e-06	4.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	1.59e-06	4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	1.59e-06	4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.59e-06	3.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.58e-06	3.98e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.58e-06	3.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.58e-06	3.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.57e-06	3.96e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.56e-06	3.93e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.54e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	1.54e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.53e-06	3.86e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	1.53e-06	3.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.52e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.52e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	1.51e-06	3.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.5e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.5e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.49e-06	3.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.49e-06	3.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.49e-06	3.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.47e-06	3.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.47e-06	3.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.47e-06	3.69e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.47e-06	3.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.46e-06	3.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.46e-06	3.68e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.46e-06	3.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	1.46e-06	3.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.43e-06	3.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.43e-06	3.6e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.43e-06	3.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.42e-06	3.57e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.42e-06	3.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.41e-06	3.54e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.4e-06	3.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.4e-06	3.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.39e-06	3.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.38e-06	3.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.38e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.37e-06	3.45e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1.37e-06	3.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.35e-06	3.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.35e-06	3.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.33e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.33e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.33e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.31e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.31e-06	3.29e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.3e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.28e-06	3.22e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.28e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.28e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	1.26e-06	3.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.25e-06	3.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.25e-06	3.14e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	1.24e-06	3.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.23e-06	3.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.22e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.21e-06	3.04e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.2e-06	3.01e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.18e-06	2.96e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.17e-06	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.17e-06	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1.16e-06	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.15e-06	2.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.15e-06	2.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.15e-06	2.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.14e-06	2.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.14e-06	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.13e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.12e-06	2.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.12e-06	2.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.12e-06	2.8e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—type 2 diabetes mellitus	1.1e-06	2.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.07e-06	2.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.06e-06	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.06e-06	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.04e-06	2.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.03e-06	2.6e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	1.02e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	1e-06	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	9.85e-07	2.48e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	9.82e-07	2.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.6e-07	2.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.48e-07	2.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.3e-07	2.34e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	9.19e-07	2.31e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.06e-07	2.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.83e-07	2.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.81e-07	2.21e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	8.79e-07	2.21e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	8.79e-07	2.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—type 2 diabetes mellitus	8.64e-07	2.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.64e-07	2.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.15e-07	2.05e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	8.04e-07	2.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.97e-07	2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	7.32e-07	1.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.14e-07	1.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.64e-07	1.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.59e-07	1.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.12e-07	1.54e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	4.04e-07	1.02e-05	CbGpPWpGaD
